Teckro Expands Its Leadership Position in Clinical Trials With New Hires Malia Lewin and Silvina Baudino to Scale Its Global Market Strategy
20.5.2021 16:04:00 EEST | Business Wire | Press release
Teckro, creator of the only clinical trials platform that facilitates collaboration and real-time decision-making between and among study stakeholders, today announces two key hires: Malia Lewin as global head of strategy and Silvina Baudino to lead the Teckro site strategy. They are the latest experienced veterans to join Teckro’s leadership team.
Other notable hires since the start of the year, include:
- Former Veeva Systems sales leaders Ciaran Avitabile and Jeremy Schwarz join as Teckro global head and US head of sales, respectively;
- Previous Salesforce solution engineering leader Brian Sharkey joins to build Teckro’s global solution consulting function;
- Cheryl Murphy, with 20+ years of experience in the pharmaceutical industry, joins as Teckro VP of customer engagement and delivery where she will lead operational excellence for a world-class customer experience.
Malia Lewin to Lead Teckro’s Strategy for Optimal Market and Product Fit
Malia Lewin has nearly 20 years of experience in the biopharma industry, serving in a variety of roles to champion new ideas, innovation and technological advancements in life sciences. Most recently, Malia was chief business officer at CherryCircle Software, a maker of cloud-based software for pharmaceutical manufacturing. Among her other roles, she served as global director of oncology strategy at Veeva Systems.
Malia says, “While clinical research pushes forward incredible scientific advancements, the management of clinical trial operations is woefully behind. This creates friction that needlessly impacts the time and cost of delivering new treatments. Teckro’s platform changes the game by allowing a seamless flow of vital information between sites and sponsors. This enables faster, safer, more efficient trials and an improved path for life-saving treatments to people around the world. ”
Silvina Baudino to Champion Teckro Requirements for Sites’ Needs
Also joining Teckro’s strategy team, Silvina Baudino brings more than 20 years of clinical trial industry experience, most recently as director of strategic site networks for IQVIA. Her career has encompassed a diverse range of responsibilities, including building and implementing innovative site-centric delivery models as well as creating strategies to improve quality and accessibility to clinical trials for patients globally.
“While public awareness and appreciation for clinical research improved with the pandemic, research site staff are struggling to work through backlogs of trials that were put on hold or delayed due to COVID-19,” Silvina explains. “Teckro is uniquely positioned to help site staff manage their demanding workloads to deliver the best outcomes for patients and preserve the quality of the research data.”
CEO Gary Hughes reflects on the current strength of Teckro, saying: “The depth of the expertise of our leadership team is testament to the belief in Teckro’s mission and our positive impact on clinical trials operations. This all-star team of leaders gives confidence to the rest of our staff, prospective employees, and our customers that we can continue to modernize and simplify clinical operations and accelerate the pace of clinical research.
Watch this short Q&A with Malia and Silvina to hear their thoughts on joining Teckro on International Clinical Trials Day and how they believe the future of clinical trials will evolve.
About Teckro
Teckro’s cloud-based clinical trial platform connects research sites, monitors and study teams with access to critical information, real-time decision support, and vital insights into clinical operations and trial performance. Teckro is used at more than 20,000 research sites and by thousands of investigators around the world. The company works with six out of the top 10 pharmaceutical companies as well as emerging biotechs. A number of trials run on Teckro are now starting to report success metrics in meeting endpoints, and others have been granted priority review by regulators in the US and Europe.
More Information:
- Visit teckro.com
- Connect with Teckro on LinkedIn
- Follow @teckroofficial on Twitter and Instagram
- Like Teckro on Facebook
- Subscribe to the Teckro YouTube channel
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210520005524/en/
Contact information
Hannah Lippitt
hannah.lippitt@teckro.com
+44 7393334501
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Teledyne FLIR Defense Launches Black Recon™ Autonomous Micro-Drone15.6.2026 07:05:00 EEST | Press release
Teledyne FLIR Defense, part of Teledyne Technologies Incorporated (NYSE: TDY), today announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone system that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260614388428/en/ Teledyne FLIR Defense announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. Black Recon allows crews to launch, operate, recover, and recharge up to three UAS without leaving their platform, reducing operator risk. Designed for vehicle integration, Black Recon allows crews to launch, operate, recover, and recharge up to three unmanned aerial systems without leaving their platform, reducing risk and accelerating decision-making. “Black Recon
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 11:00:00 EEST | Press release
OM Pharma will reveal preliminary results from the REACH study at the European Academy of Allergy and Clinical Immunology (EAACI) Congress. REACH is the first and largest multi-country real-world evidence (RWE) study to date evaluating the impact of Broncho-Vaxom® in patients with recurrent respiratory tract infections (RTIs).1,2 The findings offer critical new clinical evidence of the therapy's effectiveness in everyday clinical practice. In a real-world cohort of 15,794 paediatric (aged >1 year), adolescent, adult and elderly patients in China, Italy, and Belgium, Broncho-Vaxom® was associated with reductions in RTI recurrence and healthcare utilisation at 12 and 24 months after treatment initiation, compared with the 12 months prior to starting the therapy.1 “The REACH real-world evidence study shows that Broncho-Vaxom® can significantly reduce infections requiring medical visits across age groups and co-morbidities,” said Anna Thomas, Chief Scientific Officer at OM Pharma. “Recurre
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 18:15:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced updated clinical data from two Phase 1 studies evaluating the safety, tolerability and efficacy of INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody, in patients with mutCALR-expressing myeloproliferative neoplasms (MPNs). INCA033989 demonstrated rapid, clinically meaningful responses and consistent molecular activity across both myelofibrosis (MF) and essential thrombocythemia (ET), with convergent evidence supporting the potential for disease modification. These findings are being presented in oral and poster presentations at the European Hematology Association (EHA) 2026 Congress in Stockholm, Sweden (Session: Myeloproliferative neoplasms – Clinical, Presentation numbers: S216, PS1983, PF884). “The data presented at EHA 2026 demonstrate clinically meaningful and consistent responses with INCA033989 across both myelofibrosis and essential thrombocythemia,” said Pablo J. Cagnoni, M.D., President of Incyte and G
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi ® /Minjuvi ® ) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 13:00:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) versus R-CHOP, the current standard of care, as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). Eligible patients had an International Prognostic Index (IPI) score of 3-5, or, for patients ≤60 years of age, an age-adjusted IPI (aaIPI) of 2-3. These data are being highlighted in a prestigious Plenary Abstracts Session at the European Hematology Association (EHA) 2026 Congress, being held June 11 - 14, 2026, in Stockholm, Sweden (Abstract # S101. Plenary Abstract Session. June 13, 6:00 - 7:30 a.m. ET [12:00-1:30 p.m. CEST]). frontMIND results were als
Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202613.6.2026 00:31:00 EEST | Press release
Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
